Pharmacy Grand Rounds

Graft-Versus-Host Disease: The Enemy Within Me

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)
MN-RO-AL-MN-459-MAYO LH

Interactive Video Conference Room(s): 
MN-RO-GO-19-101 BARRETTE LH

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Graft-versus-host disease (GVHD) after solid organ transplant (SOT) is a rare complication that is associated with high mortality.  Owing to the rarity of GVHD after SOT, no evidence-based guidelines or recommendations for treatment exist. This presentation will provide an overview on the clinical aspects and pathogenesis of the condition. It will also review the available evidence for the treatment approaches that have been used in the management of GVHD after SOT.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Explain the pathophysiology of graft-versus-host disease (GVHD) in Solid Organ Transplant (SOT)
2. Recognize current therapeutic options for managing GVHD in SOT
3. Discuss the available evidence and outline recommendations for the management of GVHD in SOT

Session Announcement

Session Slides

FACULTY INFORMATION

Stephanie M. Gore, PharmD, MPH
PGY2 Solid Organ Transplant Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Stephanie received a Doctor of Pharmacy degree from Samford University McWhorter School of Pharmacy and a Master of Public Health at Samford University in Birmingham, AL with subsequent completion of PGY1 training at Virginia Commonwealth University Health System in Richmond, Virginia.  She is the current PGY2 Solid Organ Transplant Pharmacy Resident at Mayo Clinic Hospital-Rochester.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Stephanie M. Gore, PharmD, MPH
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Alefacept
    • Antithymocyte globulin - rabbit
    • Basiliximab
    • Corticosteroids
    • Daclizumab
    • Infliximab
    • Etanercept
    • Ruxolitinib

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS